ASEAN Heart Journal

First online: 

Case Reports

Heparin has No Place as an Anticoagulant in PCI – A Protagonist’s View

Tan Huay Cheem

03 December 2014

April 2014, 22:3

Case Reports

  • Facebook Social Icon
  • Twitter Social Icon
  • Google+ Social Icon

Reference Tools

References

1. Dougherty KG, Gaos CM, Bush HS et al. Activated clotting times and activated partial thromboplastin times in patients undergoing coronary angioplasty who receive bolus doses of heparin. Cathet Cardiovasc Diagn 1992; 26: 260–63

CrossRef

 

2. Ferguson JJ, Dougherty KG, Gaos CM et al. Relation between procedural activated clotting time and outcome after PTCA. J Am Coll Cardiol 1994; 23: 1061–65.

CrossRef

 

3. Bowers J, Ferguson JJ. The use of activated clotting times to monitor heparin therapy during and after interventional procedures. Clin Cardiol 1994;17:357–61

PubMed     CrossRef

 

4. Montalescot G, Collet JP, Tanguay ML et al Anti-Xa activity relates to survival and effi cacy in unselected acute coronary syndrome patients treated with enoxaparin. Circulation 2004; 110: 329–398

CrossRef

 

5. Gilchrist IC, Berkowitz SD, Thompson TD et al Heparin dosing and outcomes in acute coronary syndromes: The GUSTO-IIb experience. Global Use of Strategies to Open Occluded Coronary Arteries. Am Heart J 2002; 144: 73–80

PubMed     CrossRef

 

6. Montalescot G, White HD, Gallo R et al STEEPLE Investigators. Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention. N Engl J Med 2006; 355: 1006–1017

PubMed     CrossRef

 

7. Zalc S, Lemos PA, Esteves A et al. Early ambulation and variability in anticoagulation during elective coronary stenting with a single intravenous bolus of low-dose, low molecular weight heparin enoxaparin. J Invasive Cardiol 2006; 18: 45–48

PubMed

 

8. Smith SC Jr, Feldman TE, Hirshfeld JW Jr et al. ACC/ AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention. Circulation 2006; 113; 156–175.

 

9. White HD, Kleiman NS, Mahaffey KW et al Effi cacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial. Am Heart J 2006; 152: 1042–1050

PubMed     CrossRef

 

10. Borentain M, Montalescot G, Bouzamondo A et al Low-molecular weight heparin vs unfractionated heparin in percutaneous coronary intervention: A combined analysis. Catheter Cardiovasc Interv 2005; 65: 212–221

PubMed

 

11. Zeymer U, Gitt A, Junger C et al Effi cacy and safety of enoxaparin in unselected patients with STEMI. Thromb Haemost 2008; 99: 150–4

PubMed

 

12. Montalescot G, Ellis SG, de Belder MA et al Enoxaparin in primary and facilitated percutaneous coronary intervention: a formal prospective nonrandomized substudy of the FINESSE trial {Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events}. JACC Cardiovasc Interv 2010; 3: 203–12

PubMed     CrossRef

 

13. Montalsecot G, Zeymer U, Silvain J et al Intravenous enoxaparin or unfractionated heparin in primary percutaneous coronary intervention for ST-elevation myocardial infarction: the international randomized open-label ATOLL trial. Lancet 2011; 378: 693–703

 

14. The Task Force on Myocardial Revacsularisation of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2010; 31: 2501–2555

 

15. Levine GN, Bates ER, Blankenship JC et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol 2011; 58: e44–e122

PubMed    CrossRef

.

.

Tel No: +603-7931 7900
Fax No: +603-7932 1400

 

 

D-13A-06, Menara Suezcap 1, KL Gateway,
No.2 Jalan Kerinchi, Gerbang Kerinchi Lestari,
59200 Kuala Lumpur, Malaysia.

www.aseancardiology.org

ASEAN HEART Journal is Supported by Unrestricted Grant From 

Committed to therapeutic advances in cardiovascular research